(v) a BP-2a polypeptide comprising the amino acid sequence of SEQ ID NO:44, or an amino acid sequence having at least 70% identity to SEQ ID NO:44; and

(vi) a BP-2a polypeptide comprising the amino acid sequence of SEQ ID NO:46, or an amino acid sequence having at least 70% identity to SEQ ID NO:46; and

(vii) an spb1 polypeptide comprising amino acids 185 to 468 of SEQ ID NO:206.

6. The conjugate according to any of claims 4 to 5, wherein the polypeptide chain is of the formula NH_2-A-{-X-L-}$_n$-B-COOH, wherein: A is an optional *N*-terminal amino acid sequence; B is an optional C-terminal amino acid sequence; *n* is an integer of 2 or more (*e.g.* 2, 3, 4, 5, 6, *etc.*); each X is an amino acid sequence of a BP-2a polypeptide or a spb1 polypeptide, wherein at least one X is an BP-2a polypeptide and at least one X is an spb1 polypeptide; and L is an optional linker amino acid sequence.

7. The conjugate according to any of claims 4 to 6, wherein the polypeptide chain comprises an amino acid sequence having at least 70% identity (*e.g.* at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%) to SEQ ID NO:276, particularly an amino acid sequence of SEQ ID NO:276.

8. The conjugate according to any preceding claim, wherein the antigen is a saccharide.

9. The conjugate according to claim 8, wherein the saccharide is a capsular saccharide from *Streptococcus agalactiae*.

10. The conjugate according to claim 9, wherein the saccharide is a capsular saccharide from *Streptococcus agalactiae* serotype II or V.

11. A conjugate according to any of the preceding claims, for use in medicine.

12. A pharmaceutical composition comprising a conjugate according to any of the preceding claims in combination with a pharmaceutically acceptable carrier.

13. The pharmaceutical composition according to claim 12, comprising a mixture of conjugates comprising saccharides from at least two of *Streptococcus agalactiae* serotypes selected from the group consisting of types Ia, Ib, II, III and V.

14. The pharmaceutical composition according to claim 13, comprising (i) saccharides from *Streptococcus agalactiae* serotype Ia, Ib and III conjugated to CRM197 and (ii) a saccharide from *Streptococcus agalactiae* serotype II or V conjugated to GBS80.

15. Use of an immunologically effective amount of a conjugate according to any of claims 1-11 or a pharmaceutical composition according to any of claims 12-14 in the manufacture of a medicament for raising an immune response in a mammal.